EA200971020A1 - Лечение сердечно-сосудистого заболевания и дислипидемии с использованием ингибиторов секреторной фосфолипазы а(spla) и способы комбинированного лечения с ингибитором spla - Google Patents

Лечение сердечно-сосудистого заболевания и дислипидемии с использованием ингибиторов секреторной фосфолипазы а(spla) и способы комбинированного лечения с ингибитором spla

Info

Publication number
EA200971020A1
EA200971020A1 EA200971020A EA200971020A EA200971020A1 EA 200971020 A1 EA200971020 A1 EA 200971020A1 EA 200971020 A EA200971020 A EA 200971020A EA 200971020 A EA200971020 A EA 200971020A EA 200971020 A1 EA200971020 A1 EA 200971020A1
Authority
EA
Eurasian Patent Office
Prior art keywords
spla
inhibitors
cvd
treatment
dyslipidemia
Prior art date
Application number
EA200971020A
Other languages
English (en)
Russian (ru)
Inventor
Йоаким Триас
Колин Хислоп
Пол Труэкс
Бернадин Фрейзер
Дебра Одинк
Скотт Чадуик
Кеннет Гоулд
Патрик Эачо
Мэриэн Мозиор
Original Assignee
Антера Фармасьютикалз, Инк.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Антера Фармасьютикалз, Инк. filed Critical Антера Фармасьютикалз, Инк.
Publication of EA200971020A1 publication Critical patent/EA200971020A1/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Urology & Nephrology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
EA200971020A 2007-05-03 2008-05-02 Лечение сердечно-сосудистого заболевания и дислипидемии с использованием ингибиторов секреторной фосфолипазы а(spla) и способы комбинированного лечения с ингибитором spla EA200971020A1 (ru)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US91591007P 2007-05-03 2007-05-03
US96959107P 2007-08-31 2007-08-31
US87486907A 2007-10-18 2007-10-18
PCT/US2008/062577 WO2008137803A1 (en) 2007-05-03 2008-05-02 Treatment of cardiovascular disease and dyslipidemia using secretory phospholipase a2 (spla2) inhibitors and spla2 inhibitor combination therapies

Publications (1)

Publication Number Publication Date
EA200971020A1 true EA200971020A1 (ru) 2010-10-29

Family

ID=39943969

Family Applications (1)

Application Number Title Priority Date Filing Date
EA200971020A EA200971020A1 (ru) 2007-05-03 2008-05-02 Лечение сердечно-сосудистого заболевания и дислипидемии с использованием ингибиторов секреторной фосфолипазы а(spla) и способы комбинированного лечения с ингибитором spla

Country Status (8)

Country Link
EP (1) EP2154958A4 (ja)
JP (1) JP2010526152A (ja)
CN (1) CN101742907A (ja)
AU (1) AU2008247451A1 (ja)
BR (1) BRPI0811486A2 (ja)
CA (1) CA2686157A1 (ja)
EA (1) EA200971020A1 (ja)
WO (1) WO2008137803A1 (ja)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2749534A1 (en) * 2009-01-08 2010-07-15 Anthera Pharmaceuticals, Inc. Secretory phospholipase a2 (spla2) inhibitor and niacin drug compositions and methods for treating cardiovascular disease and dyslipidemia
RU2483707C1 (ru) * 2012-05-04 2013-06-10 Лира Талгатовна Гильмутдинова Способ санаторной терапии больных с метаболическим синдромом и артериальной гипертензией с применением сульфидных ванн
CN115040508A (zh) * 2022-07-28 2022-09-13 上海市同仁医院 吲哚-3-乙醛在制备新型抗肥胖活性制剂中的应用

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GT199800127A (es) * 1997-08-29 2000-02-01 Combinaciones terapeuticas.
SK16332000A3 (sk) * 1998-05-01 2001-06-11 Eli Lilly And Company Ester ako inhibítor spla2
AU2001236440A1 (en) * 2000-01-25 2001-08-07 Eli Lilly And Company Method for the treatment of inflammation with spla2 inhibitors
CA2417127A1 (en) * 2000-07-24 2002-01-31 The University Of Queensland Compounds and inhibitors of phospholipases
TWI314457B (ja) * 2001-03-19 2009-09-11 Shionogi & Co
WO2006034435A2 (en) * 2004-09-21 2006-03-30 Point Therapeutics, Inc. Methods and compositions for treating glucose-associated conditions, metabolic syndrome, dyslipidemias and other conditions
MX2008005666A (es) * 2005-11-03 2009-03-02 Ilypsa Inc Compuestos multivalentes de indol y uso de los mismos como inhibidores de fosfolipasa-a2.

Also Published As

Publication number Publication date
EP2154958A4 (en) 2011-05-04
BRPI0811486A2 (pt) 2014-09-30
JP2010526152A (ja) 2010-07-29
EP2154958A1 (en) 2010-02-24
CA2686157A1 (en) 2008-11-13
WO2008137803A1 (en) 2008-11-13
CN101742907A (zh) 2010-06-16
AU2008247451A1 (en) 2008-11-13

Similar Documents

Publication Publication Date Title
EA200602273A1 (ru) Замещённые гетероарильные и фенилсульфамоильные соединения
EA200701229A1 (ru) Омега-3 жирные кислоты и дислипидемический агент для липидной терапии
EA201001847A1 (ru) Соединения и композиции, применяемые для лечения малярии
ATE530540T1 (de) Pyrimidonverbindungen als gsk-3-inhibitoren
NZ743714A (en) Methods of reducing the risk of a cardiovascular event in a subject on statin therapy
BR0315381A (pt) Composto ou um sal farmaceuticamente aceitável deste, composição farmacêutica, e, métodos para inibir a atividade da enzima dipeptidil peptidase-iv em um mamìfero em necessidade disto, para tratar diabetes em um mamìfero em necessidade disto, para tratar diabete não dependente de insulina (tipo 2) em um mamìfero em necessidade disto, para tratar hiperglicemia em um mamìfero em necessidade disto, para tratar a obesidade em um mamìfero em necessidade disto, para tratar um ou mais distúrbios de lipìdios selecionados do grupo de dislipidemia, hiperlipidemia, hipertrigliceridemia, hipercolesterolemia, hdl baixo e ldl alto em um mamìfero em necessidade disto, e para tratar em um mamìfero em necessidade disto uma ou mais condições
EA200901032A1 (ru) Соединения и композиции в качестве модуляторов активности gpr119
CL2012001124A1 (es) Composición farmacéutica que comprende un extracto terapéutico concentrado, que comprende fosfolípidos en concentración de 60 a 99% y uso para tratar enfermedades cardiovasculares, reducir niveles de triglicérido, reducir colesterol ldl y aumentar colesterol hdl.
MX2009003727A (es) Acidos y esteres boronicos como inhibidores de amida hidrolasa de acido graso.
EA200870415A1 (ru) Хиназолины для ингибирования pdk 1
HK1136283A1 (en) Compounds for the prevention and treatment of cardiovascular diseases
DK2358717T3 (da) Aminotetrahydropyraner som dipeptidylpeptidase-iv-inhibitorer tilbehandling eller forebyggelse af diabetes
EA200901166A1 (ru) Соединения и композиции в качестве модуляторов активности gpr 119
TWI367886B (en) Proteasome inhibitors and methods of using the same
BR112015005117A2 (pt) métodos de tratamento da doença de alzheimer e suas composições farmacêuticas
MA32393B1 (fr) Composés et compositions servant d'inhibiteurs de kinases
EA201100138A1 (ru) 4-феноксиметилпиперидины в качестве модуляторов активности gpr119
EA200500629A1 (ru) Активаторы рецепторов, активируемых пролифератором пероксисом (ppar)
EA200970088A1 (ru) Модуляторы метаболизма и лечение связанных с ним нарушений
CY1109551T1 (el) Πρωτεασωμικοι αναστολεις και μεθοδοι χρησιμοποιησης αυτων
WO2010079431A3 (en) Compounds for the prevention and treatment of cardiovascular disease
EA200601442A1 (ru) Замещённые гетероарил- и фенилсульфамоилпроизводные
BR112014014410A2 (pt) composições e métodos que compreendem uma variante de enzima lipolítica
MA37886A1 (fr) Nouvelles pyridinones bicycliques
EA201200570A1 (ru) Соединения и композиции в качестве модуляторов активности gpr119